Grifols (GRFS) Net Cash Flow (2010 - 2020)
Grifols' (GRFS) quarterly Net Cash Flow came in at -$130.2 million in Q1 2020, up 75.96% YoY from -$74.0 million in Q2 2019, and up 59.92% on a QoQ basis from -$324.9 million in Q4 2019.
Grifols (GRFS) Net Cash Flow (2010 - 2020) Analysis & Trends
Grifols (GRFS) has 11 years of Net Cash Flow data on file, last reported at -$130.2 million in Q1 2020.
- Quarterly Net Cash Flow rose 75.96% year-over-year to -$130.2 million in Q1 2020, while the trailing twelve-month figure through Dec 2025 was $0.0 (changed 0.0% YoY) and the FY2025 annual result came in at -$71.0 million, down 115.49% from the prior year.
- Net Cash Flow grew to -$130.2 million in Q1 2020, from -$324.9 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $4.9 billion in Q4 2017 to a low of -$604.2 million in Q3 2016.
- A 5-year average of $751.8 million and a median of -$72.0 million in 2016 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2016 — Net Cash Flow plunged 322.73% — and 2017, when it jumped 6845.21%.
- Tracing GRFS's Net Cash Flow over 5 years: stood at -$72.0 million in 2016, then jumped by 6845.21% to $4.9 billion in 2017, then slumped by 72.95% to $1.3 billion in 2018, then plunged by 124.72% to -$324.9 million in 2019, then soared by 59.92% to -$130.2 million in 2020.
- The last three Net Cash Flow figures came in at -$130.2 million (Q1 2020), -$324.9 million (Q4 2019), and -$541.8 million (Q1 2019), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -1.27 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -2.82 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 1.53 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 757.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -6.80 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 1.95 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -4.43 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -722.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 2.68 Bn |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | -130.24 Mn |
| Mar 31, 2020 | -130.24 Mn |
| Dec 31, 2019 | -324.92 Mn |
| Dec 31, 2019 | -324.92 Mn |
| Mar 31, 2019 | -541.80 Mn |
| Mar 31, 2019 | -541.80 Mn |
| Dec 31, 2018 | 1.31 Bn |
| Dec 31, 2018 | 1.31 Bn |
| Jun 30, 2018 | -530.10 Mn |
| Jun 30, 2018 | -530.10 Mn |
| Mar 31, 2018 | 249.20 Mn |
| Mar 31, 2018 | 249.20 Mn |
| Dec 31, 2017 | 4.86 Bn |
| Dec 31, 2017 | 4.86 Bn |
| Jun 30, 2017 | 247.39 Mn |
| Jun 30, 2017 | 247.39 Mn |
| Mar 31, 2017 | 3.80 Bn |
| Mar 31, 2017 | 3.80 Bn |
| Dec 31, 2016 | -72.03 Mn |
| Dec 31, 2016 | -72.03 Mn |